Intrinsic and Extrinsic Apoptotic Pathway Signaling as Determinants of Histone Deacetylase Inhibitor Antitumor Activity

Advances in Cancer Research

Volumn 116, Issue , 2012, Pages 165-197

  Matthews, Geoffrey M ^a,b   Newbold, Andrea ^a,b   Johnstone, Ricky W ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Apoptosis; Bcl 2 family; Extrinsic; Intrinsic; Prosurvival; Therapy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; CASPASE 3; CASPASE 7; CASPASE 8; CYCLOHEXIMIDE; DACTINOMYCIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ENTINOSTAT; ETOPOSIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE INHIBITOR; LIGAND; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN BID; PROTEIN NOXA; PUMA PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; ROMIDEPSIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DEATH; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECT; GLYCOSYLATION; HUMAN; MESOTHELIOMA; MICROARRAY ANALYSIS; MITOCHONDRION; NONHUMAN; PALMITOYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

EID: 84867804338     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394387-3.00005-7     Document Type: Chapter

References (128)

1. Adams J.M., Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998, 281:1322-1326.
2. Amsel A.D., Rathaus M., Kronman N., Cohen H.Y. Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation. Proceedings of the National Academy of Science of the United States of America 2008, 105:5117-5122.
3. Baumann P., Junghanns C., Mandl-Weber S., Strobl S., Oduncu F., Schmidmaier R. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells. British Journal of Haematology 2012, 156:633-642.
4. Bernhard D., Ausserlechner M.J., Tonko M., Loffler M., Hartmann B.L., Csordas A., Kofler R. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. The FASEB Journal 1999, 13:1991-2001.
5. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nature Reviews. Drug Discovery 2006, 5:769-784.
6. Brunelle J.K., Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. Journal of Cell Science 2009, 122:437-441.
7. Cao X.X., Mohuiddin I., Ece F., McConkey D.J., Smythe W.R. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. American Journal of Respiratory Cell and Molecular Biology 2001, 25:562-568.
8. Carlisi D., Lauricella M., D'Anneo A., Emanuele S., Angileri L., Di Fazio P., Santulli A., Vento R., Tesoriere G. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. European Journal of Cancer 2009, 45:2425-2438.
9. Chen S., Dai Y., Pei X.-Y., Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: Evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Molecular and Cellular Biology 2009, 29:6149-6169.
10. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., Huang D.C.S. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell 2005, 17:393-403.
11. Chirakkal H., Leech S.H., Brookes K.E., Prais A.L., Waby J.S., Corfe B.M. Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding. Oncogene 2006, 25:7192-7200.
12. Cory S., Adams J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nature Reviews. Cancer 2002, 2:647-656.
13. Cory S., Huang D.C.S., Adams J.M. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
14. Cottin V., Doan J.E., Riches D.W. Restricted localization of the TNF receptor CD120a to lipid rafts: A novel role for the death domain. Journal of Immunology 2002, 168:4095-4102.
15. Dai Y., Chen S., Wang L., Pei X.-Y., Kramer L.B., Dent P., Grant S. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. British Journal of Haematology 2011, 153:222-235.
16. Dokmanovic M., Marks P.A. Prospects: Histone deacetylase inhibitors. Journal of Cellular Biochemistry 2005, 96:293-304.
17. Duckett C.S. IAP proteins: Sticking it to Smac. Biochemistry Journal 2005, 385:e1-e2.
18. Ellis L., Bots M., Lindemann R.K., Bolden J.E., Newbold A., Cluse L.A., Scott C.L., Strasser A., Atadja P., Lowe S.W., Johnstone R.W. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009, 114:380-393.
19. Ellis L., Pan Y., Smyth G.K., George D.J., McCormack C., Williams-Truax R., Mita M., Beck J., Burris H., Ryan G., Atadja P., Butterfoss D., Dugan M., Culver K., Johnstone R.W., Prince H.M. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clinical Cancer Research 2008, 14:4500-4510.
20. Elmore S. Apoptosis: A review of programmed cell death. Toxicologic Pathology 2007, 35:495-516.
21. Emanuele S., Lauricella M., Carlisi D., Vassallo B., D'Anneo A., Di Fazio P., Vento R., Tesoriere G. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007, 12:1327-1338.
22. Fandy T.E., Shankar S., Rossy D.D., Sausvilley E., Srivastava R.K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005, 7:646-657.
23. Fandy T.E., Srivastava R.K. Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins. Cancer Chemotherapy and Pharmacology 2006, 58:471-477.
24. Fantin V.R., Richon V.M. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clinical Cancer Research 2007, 13:7237-7242.
25. Frew A.J., Johnstone R.W., Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Letters 2009, 280:125-133.
26. Frew A.J., Lindemann R.K., Martin B.P., Clarke C.J.P., Sharkey J., Anthony D.A., Banks K.-M., Haynes N.M., Gangatirkar P., Stanley K., Bolden J.E., Takeda K., Yagita H., Secrist J.P., Smyth M.J., Johnstone R.W. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:11317-11322.
27. Fritsche P., Gottlicher M., Saur D., Schmid R.M., Schneider G., Schnieke A., Schuler S., Seidler B. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009, 58:1399-1409.
28. Fu H., Subramanian R.R., Masters S.C. 14-3-3 Proteins: Structure, function, and regulation. Annual Reviews in Pharmacology and Toxicology. 2000, 40:617-647.
29. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Current Cancer Drug Targets 2008, 8:132-140.
30. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Molecular Cancer Therapeutics 2003, 2:151-163.
31. Gomez-Benito M., Martinez-Lorenzo M.J., Anel A., Marzo I., Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Experimental Cell Research 2007, 313:2378-2388.
32. Gonzalvez F., Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010, 29:4752-4765.
33. Guo F., Sigua C., Tao J., Bali P., George P., Li Y., Wittmann S., Moscinski L., Atadja P., Bhalla K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Research 2004, 64:2580-2589.
34. Hacker S., Dittrich A., Mohr A., Schweitzer T., Rutkowski S., Krauss J., Debatin K.M., Fulda S. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009, 28:3097-3110.
35. Hueber A.O., Bernard A.M., Herincs Z., Couzinet A., He H.T. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Reports 2002, 3:190-196.
36. Hurwitz J.L., Stasik I., Kerr E.M., Holohan C., Redmond K.M., McLaughlin K.M., Busacca S., Barbone D., Broaddus V.C., Gray S.G., O'Byrne K.J., Johnston P.G., Fennell D.A., Longley D.B. Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. European Journal of Cancer 2012, 48:1096-1107.
37. Inoue S., Harper N., Walewska R., Dyer M.J., Cohen G.M. Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Molecular Cancer Therapy 2009, 8:3088-3097.
38. Inoue S., MacFarlane M., Harper N., Wheat L.M., Dyer M.J., Cohen G.M. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death and Differentiation 2004, 11(Suppl. 2):S193-S206.
39. Inoue S., Mai A., Dyer M.J.S., Cohen G.M. Inhibition of histone deacetylase Class I but not Class II is critical for the sensitization of leukemic cells to tumor necrosis factor-Related apoptosis-inducing ligand-induced apoptosis. Cancer Research 2006, 66:6785-6792.
40. Inoue S., Riley J., Gant T.W., Dyer M.J.S., Cohen G.M. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007, 21:1773-1782.
41. Inoue S., Walewska R., Dyer M.J.S., Cohen G.M. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 2008, 22:819-825.
42. Johnstone R.W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nature Reviews. Drug Discovery 2002, 1:287-299.
43. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature Reviews. Cancer 2008, 8:782-798.
44. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
45. Kaminskyy V.O., Surova O.V., Vaculova A., Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011, 32:1450-1458.
46. Kaufmann S.H., Karp J.E., Svingen P.A., Krajewski S., Burke P.J., Gore S.D., Reed J.C. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998, 91:991-1000.
47. Kauh J., Fan S., Xia M., Yue P., Yang L., Khuri F.R., Sun S.Y. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 2010, 5:e10376.
48. Kerr E., Holohan C., McLaughlin K.M., Majkut J., Dolan S., Redmond K., Riley J., McLaughlin K., Stasik I., Crudden M., Van Schaeybroeck S., Fenning C., O'Connor R., Kiely P., Sgobba M., Haigh D., Johnston P.G., Longley D.B. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death and Differertiation 2012, 19:1317-1327.
49. Khandelwal A., Gediya L.K., Njar V.C.O. MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. British Journal of Cancer 2008, 98:1234-1243.
50. Kim J., Guan J., Chang I., Chen X., Han D., Wang C.-Y. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. Molecular Cancer Therapeutics 2010, 9:1977-1984.
51. Kim H., Rafiuddin-Shah M., Tu H.-C., Jeffers J.R., Zambetti G.P., Hsieh J.J.D., Cheng E.H.Y. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nature Cell Biology 2006, 8:1348-1358.
52. Kurita-Ochiai T., Ochiai K., Fukushima K. Butyric-acid-induced apoptosis in murine thymocytes and splenic T- and B-cells occurs in the absence of p53. Journal of Dental Research 2000, 79:1948-1954.
53. Labi V., Erlacher M., Kiessling S., Manzl C., Frenzel A., O'Reilly L., Strasser A., Villunger A. Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates γ irradiation-induced thymic lymphoma development. The Journal of Experimental Medicine 2008, 205:641-655.
54. Lemaire M., Fristedt C., Agarwal P., Menu E., Valckenborgh E.V., De Bruyne E., Osterborg A., Atadja P., Larsson O., Axelson M., Van Camp B., Jernberg-Wiklund H., Vanderkerken K. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor Picropodophyllin. Clinical Cancer Research 2012, 18:2230-2239.
55. Ley R., Ewings K.E., Hadfield K., Cook S.J. Regulatory phosphorylation of Bim: Sorting out the ERK from the JNK. Cell Death and Differentiation 2005, 12:1008-1014.
56. Lindemann R.K., Gabrielli B., Johnstone R.W. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 2004, 3:777-786.
57. Lindemann R.K., Newbold A., Whitecross K.F., Cluse L.A., Frew A.J., Ellis L., Williams S., Wiegmans A.P., Dear A.E., Scott C.L., Pellegrini M., Wei A., Richon V.M., Marks P.A., Lowe S.W., Smyth M.J., Johnstone R.W. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:8071-8076.
58. Maiso P., Colado E., Ocio E.M., Garayoa M., Martin J., Atadja P., Pandiella A., San-Miguel J.F. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia 2009, 23:2265-2274.
59. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: Causes and therapies. Nature Reviews. Cancer 2001, 1:194-202.
60. Martin B.P., Frew A.J., Bots M., Fox S., Long F., Takeda K., Yagita H., Atadja P., Smyth M.J., Johnstone R.W. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. International Journal of Cancer 2011, 128:2735-2747.
61. Martin A.P., Park M.A., Mitchell C., Walker T., Rahmani M., Thorburn A., Häussinger D., Reinehr R., Grant S., Dent P. BCL-2 Family inhibitors enhance histone deacetylase inhibitor and Sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Molecular Pharmacology 2009, 76:327-341.
62. Meng J., Zhang H.H., Zhou C.X., Li C., Zhang F., Mei Q.B. The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways. Oncology Reports 2012, 28:384-388.
63. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., Akiyama M., Chauhan D., Munshi N., Gu X., Bailey C., Joseph M., Libermann T.A., Richon V.M., Marks P.A., Anderson K.C. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:540-545.
64. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., Schlossman R., Chauhan D., Munshi N.C., Hideshima T., Richon V.M., Marks P.A., Anderson K.C. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003, 101:4055-4062.
65. Mitsiades C.S., Poulaki V., McMullan C., Negri J., Fanourakis G., Goudopoulou A., Richon V.M., Marks P.A., Mitsiades N. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clinical Cancer Research 2005, 11:3958-3965.
66. Monneret C. Histone deacetylase inhibitors. European Journal of Medicinal Chemistry 2005, 40:1-13.
67. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Molecular Cell 2001, 7:683-694.
68. Nakata S., Yoshida T., Horinaka M., Shiraishi T., Wakada M., Sakai T. Histone deacetylase inhibitors upregulate death receptor 5//TRAIL-R2 and sensitize apoptosis induced by TRAIL//APO2-L in human malignant tumor cells. Oncogene 2004, 23:6261-6271.
69. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E.M., Ferrara F., Bresciani F., Weisz A., de Lera A.R., Gronemeyer H., Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Medicine 2005, 11:77-84.
70. Nishioka C., Ikezoe T., Yang J., Takeuchi S., Phillip Koeffler H., Yokoyama A. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leukemia Research 2008, 32:1382-1392.
71. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
72. Pacey S., Gore M., Chao D., Banerji U., Larkin J., Sarker S., Owen K., Asad Y., Raynaud F., Walton M., Judson I., Workman P., Eisen T. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investigational New Drugs 2010, 30:341-349.
73. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., Holloway A.J., Johnstone R.W. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:3697-3702.
74. Peart M.J., Tainton K.M., Ruefli A.A., Dear A.E., Sedelies K.A., O'Reilly L.A., Waterhouse N.J., Trapani J.A., Johnstone R.W. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Research 2003, 63:4460-4471.
75. Pérez-Perarnau A., Coll-Mulet L., Rubio-Patiño C., Iglesias-Serret D., Cosialls A.M., González-Gironès D.M., de Frias M., Fernández de Sevilla A., de la Banda E., Pons G., Gil J. Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics 2011, 6:1228-1235.
76. Premkumar D.R., Jane E.P., Agostino N.R., Didomenico J.D., Pollack I.F. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Molecular Carcinogenesis 2011, 10.1002/mc.21835.
77. Puthalakath H., O'Reilly L.A., Gunn P., Lee L., Kelly P.N., Huntington N.D., Hughes P.D., Michalak E.M., McKimm-Breschkin J., Motoyama N., Gotoh T., Akira S., Bouillet P., Strasser A. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 2007, 129:1337-1349.
78. Puthalakath H., Strasser A. Keeping killers on a tight leash: Transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death and Differentiation 2002, 9:505-512.
79. Rahmani M., Yu C., Dai Y., Reese E., Ahmed W., Dent P., Grant S. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Research 2003, 63:8420-8427.
80. Ralli R., Banks K.M., Wiegmans A.P., Carney D., Seymour J.F., Johnstone R.W., Alsop A.E. Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro. Leukemia 2012, 26:1433-1435.
81. Ramjaun A.R., Tomlinson S., Eddaoudi A., Downward J. Upregulation of two BH3-only proteins, Bmf and Bim, during TGF[beta]-induced apoptosis. Oncogene 2006, 26:970-981.
82. Ramsey M.R., He L., Forster N., Ory B., Ellisen L.W. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Research 2011, 71:4373-4379.
83. Ren D., Tu H.-C., Kim H., Wang G., Bean G., Takeuchi O., Jeffers J., Zambetti G., Hsieh J.-D., Cheng E.H. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 2010, 330:1390-1393.
84. Rosato R.R., Almenara J.A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Molecular Cancer Therapeutics 2003, 2:1273-1284.
85. Rosato R.R., Almenara J.A., Maggio S.C., Coe S., Atadja P., Dent P., Grant S. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Molecular Cancer Therapeutics 2008, 7:3285-3297.
86. Rosato R.R., Maggio S.C., Almenara J.A., Payne S.G., Atadja P., Spiegel S., Dent P., Grant S. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Molecular Pharmacology 2006, 69:216-225.
87. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10833-10838.
88. Safa A.R., Pollok K.E. Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel) 2011, 3:1639-1671.
89. Sanda T., Okamoto T., Uchida Y., Nakagawa H., Iida S., Kayukawa S., Suzuki T., Oshizawa T., Miyata N., Ueda R. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 2007, 21:2344-2353.
90. Sawa H., Murakami H., Ohshima Y., Sugino T., Nakajyo T., Kisanuki T., Tamura Y., Satone A., Ide W., Hashimoto I., Kamada H. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathology 2001, 18:109-114.
91. Schuler S., Fritsche P., Diersch S., Arlt A., Schmid R.M., Saur D., Schneider G. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Molecular Cancer 2010, 9:80.
92. Schwulst S.J., Muenzer J.T., Peck-Palmer O.M., Chang K.C., Davis C.G., McDonough J.S., Osborne D.F., Walton A.H., Unsinger J., McDunn J.E., Hotchkiss R.S. BIM siRNA decreases lymphocyte apoptosis and improves survival in sepsis. Shock 2008, 30:127-134.
93. Shankar S., Davis R., Singh K.P., Kurzrock R., Ross D.D., Srivastava R.K. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Molecular Cancer Therapeutics 2009, 8:1596-1605.
94. Shankar S., Singh T.R., Fandy T.E., Luetrakul T., Ross D.D., Srivastava R.K. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways. International Journal of Molecular Medicine 2005, 16:1125-1138.
95. Shao Y., Gao Z., Marks P.A., Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:18030-18035.
96. Singh T.R., Shankar S., Srivastava R.K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005, 24:4609-4623.
97. Srivastava R.K., Kurzrock R., Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Molecular Cancer Therapeutics 2010, 9:3254-3266.
98. Strait K.A., Warnick C.T., Ford C.D., Dabbas B., Hammond E.H., Ilstrup S.J. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Molecular Cancer Therapeutics 2005, 4:603-611.
99. Strasser A., O'Connor L., Dixit V. Apoptosis signaling. Annual Review of Biochemistry 2000, 69:217-245.
100. Subramanian C., Opipari A.W., Bian X., Castle V.P., Kwok R.P.S. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:4842-4847.
101. Thomas S., Thurn K.T., Bicaku E., Marchion D.C., Munster P.N. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Research and Treatment 2011, 130:437-447.
102. Tu Y., Renner S., Xu F.-H., Fleishman A., Taylor J., Weisz J., Vescio R., Rettig M., Berenson J., Krajewski S., Reed J.C., Lichtenstein A. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Research 1998, 58:256-262.
103. Vanoosten R.L., Moore J.M., Ludwig A.T., Griffith T.S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Molecular Therapeutics 2005, 11:542-552.
104. Vo D.D., Donahue T.R., de la Rocha P., Begley J.L., Yang M.-Y., Kharazi P., Prins R.M., Economou J.S., Garban H.J., Ribas A. A histone deacetylase inhibitor (HDACI) sensitizes B16 melanoma to adoptive transfer (AT) immunotherapy. Journal of Immunotherapy 2006, 29:633. 10.1097/01.cji.0000211343.73588.59.
105. Vogel S., Raulf N., Bregenhorn S., Biniossek M.L., Maurer U., Czabotar P., Borner C. Cytosolic Bax: Does it require binding proteins to keep its pro-apoptotic activity in check?. Journal of Biological Chemistry 2012, 287(12):9112-9127.
106. Vrana J.A., Decker R.H., Johnson C.R., Wang Z., Jarvis W.D., Richon V.M., Ehinger M., Fisher P.B., Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999, 18:7016-7025.
107. Waby J.S., Chirakkal H., Yu C., Griffiths G.J., Benson R.S., Bingle C.D., Corfe B.M. Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Molecular Cancer 2010, 9:275.
108. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008, 27:6207-6215.
109. Weber A., Paschen S.A., Heger K., Wilfling F., Frankenberg T., Bauerschmitt H., Seiffert B.M., Kirschnek S., Wagner H., Häcker G. BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. The Journal of Cell Biology 2007, 177:625-636.
110. Wei Y., Kadia T., Tong W., Zhang M., Jia Y., Yang H., Hu Y., Tambaro F.P., Viallet J., O'Brien S., Garcia-Manero G. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clinical Cancer Research 2010, 16:3923-3932.
111. Whitecross K.F., Alsop A.E., Cluse L.A., Wiegmans A., Banks K.-M., Coomans C., Peart M.J., Newbold A., Lindemann R.K., Johnstone R.W. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009, 113:1982-1991.
112. Wiegmans A.P., Alsop A., Bots M., Cluse L.A., Williams S.P., Banks K.-M., Ralli R., Scott C.L., Frenzel A., Villunger A., Johnstone R.W. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Research 2011, 71:3603-3615.
113. Wuilleme-Toumi S., Robillard N., Gomez P., Moreau P., Le Gouill S., Avet-Loiseau H., Harousseau J.L., Amiot M., Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005, 19:1248-1252.
114. Xargay-Torrent S., López-Guerra M., Saborit-Villarroya I., Rosich L., Campo E., Roué G., Colomer D. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clinical Cancer Research 2011, 17:3956-3968.
115. Yamaguchi H., Woods N.T., Piluso L.G., Lee H.-H., Chen J., Bhalla K.N., Monteiro A., Liu X., Hung M.-C., Wang H.-G. p53 Acetylation is crucial for its transcription-independent proapoptotic functions. Journal of Biological Chemistry 2009, 284:11171-11183.
116. Yang Y., Balch C., Kulp S., Mand M., Nephew K., Chen C. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia 2009, 11:552-563.
117. Yang Y., Zhao Y., Liao W., Yang J., Wu L., Zheng Z., Yu Y., Zhou W., Li L., Feng J., Wang H., Zhu W.-G. Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia 2009, 11:313-324.
118. Yeh C.C., Deng Y.T., Sha D.Y., Hsiao M., Kuo M.Y. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Molecular Cancer Therapeutics 2009, 8:2718-2725.
119. Yerbes R., Lopez-Rivas A. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL. Investigational New Drugs 2012, 30:541-547.
120. Yu J.W., Shi Y. FLIP and the death effector domain family. Oncogene 2008, 27:6216-6227.
121. Zacharias N., Sailhamer E., Li Y., Liu B., Butt M., Shuja F., Velmahos G., de Moya M., Alam H. Histone deacetylase inhibitors prevent apoptosis following lethal hemorrhagic shock in rodent kidney cells. Resuscitation 2011, 82:105-109.
122. Zhang Y., Adachi M., Kawamura R., Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death and Differentiation 2005, 13:129-140.
123. Zhang Y., Adachi M., Kawamura R., Zou H., Imai K., Hareyama M., Shinomura Y. Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation. Apoptosis 2006, 11:1349-1357.
124. Zhang Y., Adachi M., Zhao X., Kawamura R., Imai K. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. International Journal of Cancer 2004, 110:301-308.
125. Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Therapy 2004, 12:228-237.
126. Zhang X.D., Gillespie S.K., Borrow J.M., Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Molecular Cancer Therapeutics 2004, 3:425-435.
127. Zhang H.M., Yuan J., Cheung P., Chau D., Wong B.W., McManus B.M., Yang D. Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression. Molecular and Cell Biology 2005, 25:6247-6258.
128. Zhao Y., Tan J., Zhuang L., Jiang X., Liu E.T., Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:16090-16095.